Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.

Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.
复制标题

DOI:
10.1007/s00262-010-0945-7
复制
发表时间:
2011-03
期刊:
Cancer immunology, immunotherapy : CII
影响因子:
--
通讯作者:
Pauza CD
Pauza CD
中科院分区:
其他
文献类型:
--
作者:
Li H;Pauza CD

文献摘要

参考文献

被引文献

相似文献

利用 Vγ2Vδ2 T 细胞反应进行免疫治疗的临床策略面临着细胞水平或活性的短期增加以及无反应性的发展,从而降低了后续治疗的治疗反应。我们正在探索提高 Vγ2Vδ2 T 细胞反应产量和持久性的策略。一种方法侧重于哺乳动物雷帕霉素靶点 (mTOR),它对于调节 T 细胞代谢和功能非常重要。在 Vγ2Vδ2 T 细胞中,mTOR 在抗原刺激后磷酸化 S6K1 和 eIF4EBP1 信号中间体。雷帕霉素抑制这些磷酸化事件而不影响 Akt 或 Erk 激活,尽管对 Akt 或 Erk 的特异性抑制反过来会降低 mTOR 的激活。雷帕霉素对 T 细胞受体信号通路的影响导致经处理和抗原暴露的 Vγ2Vδ2 细胞增殖增加。雷帕霉素通过诱导从 CD62L + CD69− 到 CD62L-CD69+ 的群体转变、更高的 CD25 或 Bcl-2 表达、更低的 CCR5 水平以及增加对 Fas 介导的细胞凋亡的抵抗力来改变抗原特异性 Vγ2Vδ2 细胞的表型。这些变化与雷帕霉素促进细胞活化同时降低对 CCR5 或 Fas 信号传导可能发生的细胞死亡的敏感性一致。 Vγ2Vδ2 T 细胞抗原刺激过程中的雷帕霉素治疗可能是克服当前肿瘤免疫治疗障碍的策略。
Clinical strategies to exploit Vγ2Vδ2 T cell responses for immunotherapy are confronted with short-term increases in cell levels or activity and the development of anergy that reduces the response to therapy with succeeding treatments. We are exploring strategies to increase the yield and durability of elicited Vγ2Vδ2 T cell responses. One approach focuses on the mammalian target of rapamycin (mTOR), which is important for regulating T cell metabolism and function. In Vγ2Vδ2 T cells, mTOR phosphorylates the S6K1 and eIF4EBP1 signaling intermediates after antigen stimulation. Rapamycin inhibited these phosphorylation events without impacting Akt or Erk activation, even though specific inhibition of Akt or Erk in turn reduced the activation of mTOR. The effects of rapamycin on the T cell receptor signaling pathway lead to increased proliferation of treated and antigen-exposed Vγ2Vδ2 cells. Rapamycin altered the phenotype of antigen-specific Vγ2Vδ2 cells by inducing a population shift from CD62L + CD69−to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis. These changes were consistent with rapamycin promoting cell activation while decreasing the susceptibility to cell death that might occur by CCR5 or Fas signaling. Rapamycin treatment during antigen-stimulation of Vγ2Vδ2 T cells may be a strategy for overcoming current obstacles in tumor immunotherapy.
DOI: 10.1158/0008-5472.can-07-0199
发表时间: 2007-08-01
期刊: Cancer research
影响因子: 11.2
作者:
Dieli F;Vermijlen D;Fulfaro F;Caccamo N;Meraviglia S;Cicero G;Roberts A;Buccheri S;D'Asaro M;Gebbia N;Salerno A;Eberl M;Hayday AC
通讯作者: Hayday AC
DOI: 10.1074/jbc.m603912200
发表时间: 2006-09-01
影响因子: 4.8
作者:
Murooka, Thomas T.;Wong, Mark M.;Fish, Eleanor N.
通讯作者: Fish, Eleanor N.
DOI: 10.1086/605413
发表时间: 2009-09-15
影响因子: 6.4
作者:
Qin, Gang;Mao, Huawei;Tu, Wenwei
通讯作者: Tu, Wenwei
DOI: 10.1097/01.ju.0000154355.45816.0b
发表时间: 2005-05-01
期刊: JOURNAL OF UROLOGY
影响因子: 6.6
作者:
Liu, ZY;Guo, BL;Lopez, RD
通讯作者: Lopez, RD